Soluble E-Cadherin in Prostate Cancer as a Serum Biomarker in Contrast to Prostate Specific Antigen

Histopathology is gold standard in diagnosis of prostate cancer but it is a cumbersome method. On the other hand, prostate specific screening has revolutionized in detection of prostate cancer but due to PSA’s lack of sensitivity and as it is not cancer specific novel biomarkers are needed to improve risk assessment. To measure and compare the level of soluble E-cadherin and prostate specific antigen in the detection of prostate cancer, this cross-sectional study was conducted at the Department of Laboratory Medicine in collaboration with the Department of Urology, BSMMU, Dhaka, from March 2017 to February 2018. Total 70 patients were enrolled and divided into Group A (PCa) and Group B (BPH). Each group was consisted of 35 subjects who had histopathologically proven prostate cancer and benign prostatic hyperplasia. E-cadherin with a cut off value 7.3, 95% CI 0.91-1.00, had 74.3% sensitivity and 97.1% specificity for prediction of PCa. 80 KDa fragment of E-cadherin is more specific but was not available. Comparison of E-cadherin in prostate cancer without metastasis and with metastasis is recommended. Immunohistochemical examination of E-cadherin in biopsy sample is also recommended.